✦ LIBER ✦

Failure of Passively Administered Anti-Rh to Prevent Secondary Rh Responses

✍ Scribed by Mahes De Silva; Marcela Contreras; P. L. Mollison

Book ID: 115108884
Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 192 KB
Volume: 48
Category: Article
ISSN: 0042-9007
DOI: 10.1111/j.1423-0410.1985.tb00167.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SUPPRESSION OF Rh-IMMUNIZATION BY PASSIV

SUPPRESSION OF Rh-IMMUNIZATION BY PASSIVELY ADMINISTERED ANTI-Rh

✍ P. L. Mollison 📂 Article 📅 1968 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB

Failure to Augment Primary Rh Immunizati

Failure to Augment Primary Rh Immunization Using a Small Dose of ‘Passive’ IgG Anti-Rh

✍ Marcela Contreras; P. L. Mollison 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Massive feto-maternal haemorrhage: effec

Massive feto-maternal haemorrhage: effect of passively administered anti-D in the prevention of Rh sensitization and haemolytic disease of the newborn

✍ L. MILLS; J. A. F. NAPIER 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB

The Use of Modified Cells to Induce an A

The Use of Modified Cells to Induce an Anti-Rh Response

✍ H. H. Gunson; F. Stratton; P. K. Phillips 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB

The Use of Modified Cells to Induce an A

The Use of Modified Cells to Induce an Anti-Rh Response

✍ H. H. Gunson; F. Stratton; P. K. Phillips 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 English ⚖ 806 KB

Efficacy of rhesus antibodies (anti-Rh0

Efficacy of rhesus antibodies (anti-Rh0 (D)) in autoimmune thrombocytopenia: Correlation with response to high dose IgG and the degree of haemolysis

✍ Panzer, S. ;Gr�mayer, E. R. ;Haas, O. A. ;Niessner, H. ;Graninger, W. 📂 Article 📅 1986 🏛 Springer-Verlag ⚖ 233 KB

We have compared the efficacy of high-dose IgG with that of Rhesus antibodies (anti-Rh0 (D)) in 5 patients with autoimmune thrombocytopenic purpura (3 adults and 2 children). Although only transient, high-dose IgG (0.4 g/kg X 5 days) was effective in all patients (peak values 50-200 X 10(9)/1), wher